← Back to Search

Radiation Therapy

SBRT for Prostate Cancer (SOLAR-P Trial)

N/A

Waitlist Available

Led By Anand Swaminath, MD

Research Sponsored by Hamilton Health Sciences Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 1 year

Awards & highlights

SOLAR-P Trial Summary

This trial is testing a new, more focused form of radiation therapy to see if it can more effectively relieve pain from bone metastases in certain types of cancer.

Eligible Conditions

Bone Metastases
Prostate Cancer
Breast Cancer
Kidney Cancer
Melanoma

SOLAR-P Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Acute Toxicity

Late Toxicity

Local Control

+3 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183

21%

Fatigue

13%

Nausea

11%

Back pain

Shortness of Breath

Anemia

Abdominal pain

Diarrhea

Pneumonia

Kidney Injury and/or Infection

Dyspnea

Weight Loss

Malnutrition, Hypercalcemia and Weakness

Pneumothorax

Intractable pain, back pain, hip pain

Activated partial thromboplastin time prolonged

Pleural effusion

Atrial fibrillation with rapid ventricular response

Thrombocytopenia

Respiratory failure

Skin rash

colitis

100%

80%

60%

40%

20%

Study treatment Arm

Single Arm

SOLAR-P Trial Design

1Treatment groups

Experimental Treatment

Group I: Stereotactic Body RadiotherapyExperimental Treatment1 Intervention

High dose SBRT to lesion(s) of interest.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

SBRT

2014

Completed Phase 2

~1060

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Hamilton Health Sciences CorporationLead Sponsor

368 Previous Clinical Trials

300,961 Total Patients Enrolled

1 Trials studying Prostate Cancer

20 Patients Enrolled for Prostate Cancer

Juravinski Cancer Centre FoundationOTHER

11 Previous Clinical Trials

1,877 Total Patients Enrolled

Anand Swaminath, MDPrincipal InvestigatorHamilton Health Sciences Corporation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the size of this particular experimental cohort?

"Affirmative. According to clinicaltrials.gov, the study is currently accepting applications from interested participants and was last revised on July 26th 2021 after first being posted on December 4th 2020. The medical trial is planning to enlist 40 patients at a single location."

Answered by AI

Are applications still being taken for this experiment?

"Correct. Records hosted on clinicaltrials.gov verify that this investigation, which was originally posted on December 4th 2020, is actively recruiting patients. Approximately 40 individuals ought to be enrolled from 1 clinic site."

Answered by AI

Recent research and studies

Radiation OncologyJournal

Stereotactic Body Radiotherapy for Osseous Low Alpha–beta Resistant Metastases for Pain Relief—solar-p

Nguyen, Eric K., Kimmen Quan, Sameer Parpia, Stephan Tran, and Anand Swaminath. 2021. “Stereotactic Body Radiotherapy for Osseous Low Alpha–beta Resistant Metastases for Pain Relief—solar-p”. Radiation Oncology. Springer Science and Business Media LLC. doi:10.1186/s13014-021-01897-0.

clinicaltrials.govStudy

Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief

2020. "Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04177056.